Challenges in randomized controlled trials and emerging multiple sclerosis therapeutics

Neuroscience Bulletin

Volumn 31, Issue 6, 2015, Pages 745-754

  Huang, DeRen ^a  

^a Neurology and Neuroscience Associates   (United States)

Author keywords

Asia; clinical trials; immunomodulatory treatment; immunosuppression; multiple sclerosis; research ethics

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; FAMPRIDINE; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; PEGINTERFERON BETA1A; TERIFLUNOMIDE;

ASIA; ASIAN; CLINICAL FEATURE; DISABILITY; DISEASE ACTIVITY; DISEASE COURSE; DRUG MARKETING; EUROPE; HEALTH CARE POLICY; HUMAN; IMMUNOMODULATION; MEDICAL ETHICS; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NEUROLOGIST; NORTH AMERICA; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; TREATMENT RESPONSE; ETHICS; PROCEDURES;

HUMANS; IMMUNOMODULATION; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84949094395     PISSN: 16737067     EISSN: 19958218     Source Type: Journal    
DOI: 10.1007/s12264-015-1560-6     Document Type: Review

References (38)

1. Birnbaum G. Current and future treatments for relapsingremitting multiple sclerosis. Curr Opin Drug Discov Devel 2010, 13: 214–225.
2. Cross AH, Naismith RT. Established and novel diseasemodifying treatments in multiple sclerosis. J Intern Med 2014, 275: 350–363.
3. Mitsumoto J, Dorsey ER, Beck CA, Kieburtz K, Griggs RC. Pivotal studies of orphan drugs approved for neurological diseases. Ann Neurol 2009, 66: 184–190.
4. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012, 367: 1087–1097.
5. Phillips JT, Fox RJ. BG-12 in multiple sclerosis. Semin Neurol 2013, 33: 56–65.
6. Cohen JA, Chun J. Mechanisms of fingolimod’s efficacy and adverse effects in multiple sclerosis. Ann Neurol 2011, 69: 759–777.
7. Hartung HP. Interferon beta-1a for multiple sclerosis: old drug, new clothes. Lancet Neurol 2014, 13: 638–639.
8. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010, 362: 402–415.
9. Kappos L, Radue EW, O’ Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010, 362: 387–401.
10. Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs 2014, 74: 659–674.
11. Confavreux C, O’Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet Neurol 2014, 13: 247–256.
12. Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014, 13: 977–986.
13. O’Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011, 365: 1293–1303.
14. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012, 367: 1098–1107.
15. Polman CH, O’ Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354: 899–910.
16. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006, 354: 911–923.
17. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012, 380: 1829–1839.
18. Menge T, Stuve O, Kieseier BC, Hartung HP. Alemtuzumab: the advantages and challenges of a novel therapy in MS. Neurology 2014, 83: 87–97.
19. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012, 380: 1819–1828.
20. Saunders J, Wainwright P. Risk, Helsinki 2000 and the use of placebo in medical research. Clin Med 2003, 3: 435–439.
21. Salako SE. The declaration of Helsinki 2000: ethical principles and the dignity of difference. Med Law 2006, 25: 341–354.
22. Emanuel EJ, Miller FG. The ethics of placebo-controlled trials—a middle ground. N Engl J Med 2001, 345: 915–919.
23. Polman CH, Reingold SC, Barkhof F, Calabresi PA, Clanet M, Cohen JA, et al. Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology 2008, 70: 1134–1140.
24. Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, et al. Pegylated interferon beta-1a for relapsingremitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 2014, 13: 657–665.
25. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007, 6: 805–815.
26. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica (Devic’s syndrome). Handb Clin Neurol 2014, 122: 581–599.
27. Cheng Q, Miao L, Zhang J, Guan YT, Liu ZG, Wang X, et al. Clinical features of patients with multiple sclerosis from a survey in Shanghai, China. Mult Scler 2008, 14: 671–678.
28. Cheng Q, Miao L, Zhang J, Ding SJ, Liu ZG, Wang X, et al. A population-based survey of multiple sclerosis in Shanghai, China. Neurology 2007, 68: 1495–1500.
29. Houzen H, Niino M, Kikuchi S, Fukazawa T, Nogoshi S, Matsumoto H, et al. The prevalence and clinical characteristics of MS in northern Japan. J Neurol Sci 2003, 211: 49–53.
30. Houzen H, Niino M, Hirotani M, Fukazawa T, Kikuchi S, Tanaka K, et al. Increased prevalence, incidence, and female predominance of multiple sclerosis in northern Japan. J Neurol Sci 2012, 323: 117–122.
31. Wasay M, Khatri IA, Khealani B, Sheerani M. MS in Asian countries. Int MS J 2006, 13: 58–65.
32. Cree BA, Khan O, Bourdette D, Goodin DS, Cohen JA, Marrie RA, et al. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology 2004, 63: 2039–2045.
33. Bertolotto A, Gilli F. Interferon-beta responders and nonresponders. A biological approach. Neurol Sci 2008, 29 Suppl 2: S216–217.
34. Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010, 17: 1019–1032.
35. Kim SH, Huh SY, Kim W, Park MS, Ahn SW, Cho JY, et al. Clinical characteristics and outcome of multiple sclerosis in Korea: does multiple sclerosis in Korea really differ from that in the Caucasian populations? Mult Scler 2013, 19: 1493–1498.
36. Saida T, Kikuchi S, Itoyama Y, Hao Q, Kurosawa T, Nagato K, et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Mult Scler 2012, 18: 1269–1277.
37. Kira J, Itoyama Y, Kikuchi S, Hao Q, Kurosawa T, Nagato K, et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurol 2014, 14: 21.
38. Shi FD, Jia JP. Neurology and neurologic practice in China. Neurology 2011, 77: 1986–1992.